The use of generic DAAs for hepatitis C treatment, Freeman et al 2016

The use of generic DAAs for hepatitis C treatment, Freeman et al 2016

Download PDF

/ News

Share the Post

Related Posts

2018 IAS Brief Document Ending an Epidemic – Prioritizing People Who Inject Drugs in HCV elimination Efforts.
Letter from Community in Asia and Eastern Europe to Global Fund Board for Financing Hep C Treatment
Letter from Asian community and treatment advocates to Chief Executive Officer of CHAI regarding the Quick start program and concerns that patients would have to pay for sofosbuvir and diagnostics to be a part of the program in October 2016
The Updated Pricing of Ledipasvir and Sofosbuvir Co-formulated tablets
Hepatitis C Treatment Snapshots: ledipasvir and sofosbuvir co-formulation
BMS’ patent bid for Hep C treatment Daclatasvir Challenged
Asia-Pacific Aids Groups Express Deep Dismay At Conclusion Of Secretly Negotiated Trans-Pacific Partnership Agreement That Threatens Future Access To Affordable Generic Medicines And Sustainable Development Goals
Support letter for inclusion of Daclatasvir on 4th March, 2015.